Synergistic efficacy of 3n-butyrate and 5-fluorouracil in human colorectal cancer xenografts via modulation of DNA synthesis

Gastroenterology

Volumn 120, Issue 4, 2001, Pages 874-888

  Bras Gonçalves, Rui Alberto ^a   Pocard, Marc ^a   Formento, Jean Louis ^a   Poirson Bichat, Florence ^a   De Pinieux, Gonzague ^a   Pandrea, Ivona ^b   Arvelo, Francisco ^c   Ronco, Gino ^e   Villa, Pierre ^e   Coquelle, Arnaud ^a   Milano, Gérard ^d   Lesuffleur, Thécla ^a,b,c,d,e   Dutrillaux, Bernard ^a   Poupon, Marie France ^a  

^a INSTITUT CURIE   (France)

^b CENTRE ANTOINE LACASSAGNE   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^e UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 O BUTANOYL 1,2 O ISOPROPYLIDENE ALPHA DEXTRO GLUCOFURANOSE; BROXURIDINE; BUTYRIC ACID DERIVATIVE; FLUOROURACIL; MESSENGER RNA; METHOTREXATE; OXALIPLATIN; PROTEIN P53; RALTITREXED; THYMIDINE; THYMIDINE KINASE; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE MUTATION; HOMEOSTASIS; HUMAN; HUMAN CELL; MALE; METASTASIS; MICROSATELLITE INSTABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; TUMOR XENOGRAFT;

EID: 0035123710     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2001.22440     Document Type: Article

References (54)

1. Genetic alterations during colorectal-tumor development
2. Existence of two distinct processes of chromosomal evolution in near-diploid colorectal tumors
3. Association of p53 mutations with short survival in colorectal cancer
4. Alternative genetic pathways in colorectal carcinogenesis
5. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer
6. Inactivation of p53 in normal human cells increases G2/M arrest and sensitivity to DNA-damaging agents
7. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents
8. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wildtype p53 gene
9. p53 status and the efficacy of cancer therapy in vivo
10. Response to 5-fluorouracil of orthotopically xenografted human colon cancers with a microsatellite instability: Influence of P53 status
11. Prognostic factors of advanced colorectal cancers
12. Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status
13. Activity of thymidylate synthetase, thymidine kinase and galactokinase in primary and xenografted human colorectal cancers in relation to their chromosomal patterns
14. Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil
15. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil
16. Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: Allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans
17. Experimental studies on potentiation of the antitumor activity of 5-fluorouracil with 3′-azido-3′-deoxythymidine for the gastric cancer cell line MKN28 in vivo
18. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose feucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study
19. Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the I-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer
20. Modulation of colonic epithelial cell proliferation, histone acetylation, and luminal short chain fatty acids by variation of dietary fiber (wheat bran) in rats
21. Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines
22. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): Dependence on protein synthesis and synergy with a mitochondrial/ cytochrome c-dependent pathway
23. Role of butyric acid and its derivatives in the treatment of colorectal cancer and hemoglobinopathies
24. N, N-Dimethylformamide and sodium butyrate modulation of the activities of purine-metabolizing enzymes in cultures human colon carcinoma cells
25. Differential effects of sodium butyrate and hyperosmolality on the modulation of alkaline phosphatases of LoVo cells
26. Suppression of histone deacetylation in vivo and in vitro by sodium butyrate
27. Sodium butyrate induces retinoblastoma protein dephosphorylation, p16 expression and growth arrest of colon cancer cells
28. Regioselective synthesis and biological profiling of butyric and phenylalkylcarboxylic esters derivated from D-mannose and xylitol: Influence of alkyl chain length on acute toxicity
29. New stable butyrate derivatives alter proliferation and differentiation in human mammary cells
30. Response of small-cell lung cancer xenografts to chemotherapy: Multidrug resistance and direct clinical correlates
31. Different p53 mutations produce distinct effects on the ability of colon carcinoma cells to become blocked at the G1/S boundary after irradiation
32. Effect of pancreatic islets on splenic hepatocellular transplantation
33. Efficiency of orthotopic xenograft models for human colon cancers
34. Growth adaptation to methotrexate of HT-29 human colon carcinoma cells is associated with their ability to differentiate into columnar absorptive and mucus-secreting cells
35. Potentiation of lonidamine and diazeoam, two agents acting on mitochondria, in human glioblastoma treatment
36. Methionine deprivation and methionine analogs inhibit cell proliferation and growth of human xenografted gliomas
37. Thymidylate synthase expression and activity: Relation to S-phase parameters and 5-fluorouracil sensitivity
38. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion
39. Adaptation to 5-fluorouracil of the heterogeneous human colon tumor cell line HT-29 results in the selection of cells committed to differentiation
40. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma
41. Participation of p53 protein in the cellular response to DNA damage
42. Gene dosage and expression, and enzyme activity of thymidine kinase and thymidylate synthase in xenografted colorectal adenocarcinomas
43. Pyrimidine metabolism in human leukocytes. The utilization of thymine for DNA-thymine synthesis by leukemic leukocytes
44. Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity
45. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase
46. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil
47. Effect of leucovorin on 5-fluorouracil induced inhibition of thymidylate synthase in patients with colon cancer
48. Differential effects of butyrate derivatives on human breast cancer cells grown as organotypic nodules in vitro and as xenografts in vivo
49. Direct inhibition of the expression of cyclin D1 gene by sodium butyrate
50. Reciprocal regulation of α-fetoprotein and albumin gene expression by butyrate in human hepatoma cells
51. Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line
52. Butyrate inhibits seeding and growth of colorectal metastases to the liver in mice
53. Butyrate in the treatment of sickle cell disease and beta-thalassemia
54. Allelic profiles of mononucleotide repeat microsatellites in control individuals and in colorectal tumors with and without replication errors